Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Myriad Genetics, Inc’s stock clocked out at $9.73, down -2.51% from its previous closing price of $9.98. In other words, the price has decreased by -$2.51 from its previous closing price. On the day, 0.58 million shares were traded. MYGN stock price reached its highest trading level at $10.06 during the session, while it also had its lowest trading level at $9.66.
Ratios:
To gain a deeper understanding of MYGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.65 and its Current Ratio is at 1.82. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on March 12, 2025, Upgraded its rating to Overweight and sets its target price to $12.50 from $11.50 previously.
On February 12, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $29.
On December 10, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $18.UBS initiated its Neutral rating on December 10, 2024, with a $18 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 11 ’24 when DIAZ PAUL J sold 15,000 shares for $22.93 per share. The transaction valued at 343,950 led to the insider holds 962,378 shares of the business.
DIAZ PAUL J bought 15,000 shares of MYGN for $343,950 on Oct 11 ’24. On Aug 21 ’24, another insider, Ancona Margaret, who serves as the Officer of the company, bought 11,538 shares for $27.82 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 911264128 and an Enterprise Value of 926337216. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06 while its Price-to-Book (P/B) ratio in mrq is 1.27. Its current Enterprise Value per Revenue stands at 1.106 whereas that against EBITDA is -34.565.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.85, which has changed by -0.54532707 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $29.30, while it has fallen to a 52-week low of $9.36. The 50-Day Moving Average of the stock is -18.86%, while the 200-Day Moving Average is calculated to be -51.05%.
Shares Statistics:
It appears that MYGN traded 1.10M shares on average per day over the past three months and 925770 shares per day over the past ten days. A total of 91.30M shares are outstanding, with a floating share count of 87.16M. Insiders hold about 4.54% of the company’s shares, while institutions hold 101.81% stake in the company. Shares short for MYGN as of 1740700800 were 4906767 with a Short Ratio of 4.48, compared to 1738281600 on 4859938. Therefore, it implies a Short% of Shares Outstanding of 4906767 and a Short% of Float of 7.510000499999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Current recommendations for the stock of the company come from 14.0 analysts. The consensus estimate for the next quarter is $0.02, with high estimates of $0.09 and low estimates of -$0.03.
Analysts are recommending an EPS of between $0.1 and -$0.08 for the fiscal current year, implying an average EPS of $0.07. EPS for the following year is $0.27, with 16.0 analysts recommending between $0.69 and $0.04.
Revenue Estimates
In the current quarter, 14 analysts expect revenue to total $201.15M. It ranges from a high estimate of $211M to a low estimate of $197M. As of the current estimate, Myriad Genetics, Inc’s year-ago sales were $202.2MFor the next quarter, 14 analysts are estimating revenue of $212.77M. There is a high estimate of $222M for the next quarter, whereas the lowest estimate is $204M.
A total of 16 analysts have provided revenue estimates for MYGN’s current fiscal year. The highest revenue estimate was $879.5M, while the lowest revenue estimate was $840M, resulting in an average revenue estimate of $849.74M. In the same quarter a year ago, actual revenue was $837.6MBased on 16 analysts’ estimates, the company’s revenue will be $928.16M in the next fiscal year. The high estimate is $1.04B and the low estimate is $896.8M.
